Mankind Pharma shareholders approve Anish Bafna as independent director
- Mankind Pharma shareholders appointed Anish Vanraj Bafna as an independent director for a five-year term
- The special resolution passed with 99.96% of valid votes in favor
- Promoters voted unanimously in favor, holding 299,960,612 shares
- Total participation rate stood at 95.93% of outstanding shares
- No invalid votes were recorded during the remote e-voting process
*this image is generated using AI for illustrative purposes only.
Mankind Pharma shareholders approved the appointment of Anish Vanraj Bafna as a non-executive independent director. The special resolution passed on September 17, 2026, following a remote e-voting process that concluded on the same date.
The voting period ran from August 19, 2026, at 9:00 am to September 17, 2026, at 5:00 pm. Neelesh Kumar Jain of N.K.J. & Associates served as the scrutinizer for the process. The resolution requires a five-year term for Bafna, commencing from August 10, 2026.
Voting Breakdown
Promoter and promoter group entities held 299,960,612 shares and voted unanimously in favor of the resolution. Public institutional investors cast 85,102,048 votes, with 99.83% supporting the appointment. Non-institutional public shareholders polled 11,142,124 votes, showing 99.99% support.
| Category | Shares Held | Votes Polled | Votes In Favor | Votes Against |
|---|---|---|---|---|
| Promoter and Promoter Group | 299,960,612 | 299,960,612 | 299,960,612 | 0 |
| Public-Institutions | 91,471,960 | 85,102,048 | 84,955,538 | 146,510 |
| Public-Non Institutions | 21,563,406 | 11,142,124 | 11,140,823 | 1,301 |
| Total | 412,995,978 | 396,204,784 | 396,056,973 | 147,811 |
The total valid votes cast were 396,204,784 out of 412,995,978 shares held as on the record date of August 14, 2026. This represents a participation rate of 95.93%. No invalid votes were recorded in any category.
What the Numbers Show
The promoter group’s complete alignment with the resolution underscores strong internal consensus on board composition changes. While public institutional investors showed near-unanimous support, their participation rate of 93.04% was slightly higher than the 51.67% turnout from non-institutional retail shareholders, indicating varying levels of engagement across shareholder segments.
Historical Stock Returns for Mankind Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.40% | +1.55% | -5.16% | +9.80% | -10.50% | +61.71% |
How is Anish Vanraj Bafna's specific expertise expected to influence Mankind Pharma's strategic direction during his five-year tenure?
What impact might this board composition change have on Mankind Pharma's corporate governance ratings or investor confidence in the near term?
Could the high promoter voting alignment signal upcoming major strategic shifts or capital allocation decisions for the company?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
